Searching journal content for animal models (as phrase) in full text.

Displaying results 1-10 of 245
For checked items
  1. Research:
    • Keren Cohen,
    • Uri Abadi,
    • Aleck Hercbergs,
    • Paul J Davis,
    • Martin Ellis,
    • and Osnat Ashur-Fabian
    The induction of myeloma cell death and DNA damage by tetrac, a thyroid hormone derivative Endocr Relat Cancer ERC-17-0246, doi:10.1530/ERC-17-0246 first published on 10 October 2017
    ...animal models to reduce cancer cell 38 proliferation, cell migration and angiogenesis (Mousa, et al. 2008; Mousa, et al. 2012; 39 Rebbaa, et al. 2008; Yalcin, et al. 2009), to induce apoptosis in tumor cells (Glinskii, et 40 al. 2009; Yalcin, et al. 2010) and to foster DNA double-strand breaks (Hber ~~~
  2. Editorial:
    • Frank Weber and
    • Lois M Mulligan
    Happy 20th anniversary MEN1: from positional cloning to gene function restoration Endocr Relat Cancer 24 (10) E7-E11, doi:10.1530/ERC-17-0346
    ...animal models for MEN1 research and provide us with their vision for future developments (Mohr & Pellegata 2017). The management of patients with MEN1 has changed dramatically over the last two decades. We are able to control gastric acid hypersecretion due to Zollinger– Ellison Syndrome (ZES) as on ~~~
  3. Thematic Review:
    • Hermine Mohr and
    • Natalia S Pellegata
    Animal models of MEN1 Endocr Relat Cancer 24 (10) T161-T177, doi:10.1530/ERC-17-0249 first published on 25 July 2017
    ...animal models of the MEN1 syndrome have been generated in different organisms by introducing loss-of-function mutations in the orthologues of the human MEN1 gene. In this review, we will discuss MEN1 and MEN1-like models in Drosophila, mice and rats. These model systems with their specific advantage ~~~
  4. Review:
    • Lucas Leite Cunha,
    • Marjory Alana Marcello,
    • Vinicius Rocha-Santos,
    • and Laura Sterian Ward
    Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way Endocr Relat Cancer ERC-17-0222, doi:10.1530/ERC-17-0222 first published on 11 September 2017
    ...animal models augments immune responses, resulting in the 84 rejection of tumors, including pre-established tumors. Interestingly, this also results in immunity 85 against secondary exposure to tumor cells, suggesting that the memory component of immune 86 response can be evoked by anti CTLA-4 antib ~~~
  5. Research:
    • Gadi Shlomai,
    • Zara Zelenko,
    • Irini Markella Antoniou,
    • Marilyn Stasinopoulos,
    • Aviva Tobin-Hess,
    • Michael P Vitek,
    • Derek LeRoith,
    • and Emily Jane Gallagher
    OP449 inhibits breast cancer growth without adverse metabolic effects Endocr Relat Cancer 24 (10) 519-529, doi:10.1530/ERC-17-0077
    ...animal models ~~~
  6. Thematic Review:
    • Shivangi Agarwal and
    • Dileep Varma
    Targeting mitotic pathways for endocrine-related cancer therapeutics Endocr Relat Cancer 24 (9) T65-T82, doi:10.1530/ERC-17-0080 first published on 14 June 2017
    ...animal models (Pai et al. 2006, Akar  et  al. 2008, Qin  et  al. 2013, Zhang  et  al. 2013b). Long-lasting RNAi-based gene silencing can also be achieved using lentivirus-based expression systems (Park 2007). Nonetheless, significant obstacles such as in vivo delivery, partial suppression of target ~~~
  7. Review:
    • Takuma Uo,
    • Stephen R Plymate,
    • and Cynthia C Sprenger
    Allosteric alterations in the androgen receptor and activity in prostate cancer Endocr Relat Cancer 24 (9) R335-R348, doi:10.1530/ERC-17-0108
    ...animal models bearing castration-resistant, enzalutamideresistant xenografts, treatment with bromodomain inhibitors decreased AR-V7 production in association with a decrease in U2AF65 and ASF/SF2 mRNA (Asangani et al. 2016). Several studies have also demonstrated that both c-MYC and NF-kappaB2/p52 i ~~~
  8. Research:
    • Tahmineh Tabrizian,
    • Donghai Wang,
    • Fangxia Guan,
    • Zunju Hu,
    • Amanda P Beck,
    • Fabien Delahaye,
    • and Derek M Huffman
    Apc inactivation, but not obesity, synergizes with Pten deficiency to drive intestinal stem cell-derived tumorigenesis Endocr Relat Cancer 24 (6) 253-265, doi:10.1530/ERC-16-0536 first published on 28 March 2017
    ...animal models ~~~
  9. Review:
    • Georgios K Dimitriadis,
    • Anna Angelousi,
    • Martin O Weickert,
    • Harpal S Randeva,
    • Gregory Kaltsas,
    • and Ashley Grossman
    Paraneoplastic endocrine syndromes Endocr Relat Cancer 24 (6) R173-R190, doi:10.1530/ERC-17-0036 first published on 24 March 2017
    ...animal models (Gilmore  et  al. 2009). This is a potential mechanism of non-endocrine neoplasia induced hypalcaemia. Breast and testicular malignancies, and certain haematological malignancies including multiple myeloma, lymphomas and chronic lymphocytic leukaemia, can cause hypalcaemia via this mec ~~~
  10. Research:
    • Alyson Murray,
    • Stephen F Madden,
    • Naoise C Synnott,
    • Rut Klinger,
    • Darran O'Connor,
    • Norma O'Donovan,
    • William Gallagher,
    • John Crown,
    • and Michael J Duffy
    Vitamin D receptor as a target for breast cancer therapy Endocr Relat Cancer 24 (4) 181-195, doi:10.1530/ERC-16-0463 first published on 17 February 2017
    ...animal models investigated (Verlinden  et  al. 2000, Swami et al. 2012). This enhanced potency in blocking cell proliferation when combined with its lower calcaemic-inducing properties prompted us to further investigate inecalcitol as a potential new therapeutic for breast cancer. Here, we show that ~~~
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. November 2017, 24 (11)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most